fashion -WSS

fashion

author：Wikipedia 2025-10-01 01:53:55 - browse：1674

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： A deep dive into Applied Therapeutics’ data, and questions on Cassava

entertainment

WSS

Mayo Clinic plans $5B tech

Sen. Paul opposes bill to ban Chinese biotechs

FDA investigates CAR

CDC marks new Covid

BIO selects John Crowley as new CEO

UnitedHealth quietly bought dozens of outpatient centers

entertainment

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Medicare proposal to cover medical devices draws a mixed reaction

Amylyx ALS drug failure raises questions and concerns

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Despite FDA concern, risk that CAR

Affirmative action in medical school literally saved lives

Mayo Clinic plans $5B tech

Medicare details structure of new drug price negotiation program

A deep dive into Applied Therapeutics’ data, and questions on Cassava

focus

U.K. Biobank has 500,000 peoples' genome sequences available

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

UnitedHealth quietly bought dozens of outpatient centers

CDC director unscathed in first congressional testimony

With psoriasis trial ahead, Alumis raises $259 million

Organ aging and disease risk measured by new blood test

entertainment

explore

entertainment

explore